Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia. The answer to the question whether adjuvant chemotherapy and radiotherapy will improve survival from the disease can only come from randomised, controlled trials. In the future, immunotherapy and gene therapy may be of benefit but these are still many
years from the clinical arena. We believe that current evidence suggests that patients with Dukes' B and C colorectal cancer should be entered into trials of adjuvant therapy. This evidence is reviewed below along with estimates of the impact that adjuvant therapy would have on the outcome from this disease in Northern Ireland.
There are approximately 600 new cases of newly-diagnosed pathologically proven colorectal carcinoma in Northern Ireland annually.' This disease accounts for an average of 440 deaths yearly in our community.2 Colorectal cancer is the second most common cause of death from malignancy in adults in this population. The Northern Ireland colorectal cancer register has found that the proportion of tumours using Dukes' staging was as follows: Dukes' A 4%, Dukes' B 50%, Dukes' C 28%, Dukes' D 18%. These figures were calculated using the Astler-Coller Modification of Dukes' staging:3 A -mucosal (ie intramucosal and submucosal), B -into or through the colonic muscle wall, C -one or more lymph nodes involved, and D -distant metastases present. Survival figures for colorectal cancer have not improved over the last few decades despite advances in medical care. Using the above version of Dukes' staging, five-year survival figures 4 are: A -virtually 100%; B -range 30%-85%, average 70%; C -range 30%-60%, average 45%; and Dunder 5%.
Potentially curative surgery is possible in around 75% of new cases of colorectal cancer, but long-term follow-up reveals that around half of these "cured" patients will develop incurable recurrence of colorectal cancer. Previous trials have shown that 5-fluorouracil, either singly or in combination with other agents is the most effective adjuvant systemic chemotherapeutic orotate in the de-novo or salvage pathways of generation of uridine nucleotides producing a cytotoxic insult through effects on translation, transcription, mitosis or DNA synthesis.8 Folinic acid in combination with 5-fluorouracil is more effective than 5-fluorouracil alone due to inhibition of thymidylate synthetase.9 A combination of 5-fluorouracil and folinic acid would be administered according to the 48-hour infusion regime used by the ICRF medical oncology department at St Bartholomew's Hospital.10 Chemotherapy should commence at two weeks postoperatively unless there are wound or other postoperative complications and must occur within six weeks of surgery. Folinic acid is administered at 200mg/M2 (maximum dose 350mg) by intravenous infusion in 250ml normal saline over two hours. This is followed by an intravenous bolus of 400mg/M2 5-fluorouracil in 100ml normal saline over 15 minutes followed by an intravenous infusion of 400 mg/M2 5-fluorouracil in 1000ml normal saline over 18 hours. The above regimen is given on two consecutive days as an in-patient and repeated every two weeks for a total of eight courses (sixteen days of in-patient stay over four months). The original report of this regimen showed a low incidence of toxicity. In 64 patients with advanced adenocarcinoma, none had toxic effects greater than WHO Grade 11, 9% developed mucositis, 12% diarrhoea and 3% significant neutropaenia. No dose-reduction was necessary and 97% of treatments were given as planned. It is expected that these figures will be even better when given in an adjuvant setting, as has already been the experience in the Northern Ireland Centre For Clinical Oncology. When this regimen was used in Belvoir Park Hospital as adjuvant treatment for colorectal cancer, gastrointestinal upset occurred in under 10% of cases and significant neutropenia has not occurred. The 48 hour infusion schedule results in much lower toxicity and emergency hospital admissions than schedules using daily bolus injections. Data from Austria from a randomised trial on the use of modulated 5-fluorouracil in advanced disease suggests that chemotherapy often results in mild to moderate gastrointestinal symptoms6 but does not result in a decrease in quality of life scores. Indeed, in patients with poor quality of life from symptoms of their disease before treatment, there was an improvement with chemotherapy.
Radiotherapy
The area most at risk of local recurrence of rectal cancer below the peritoneal reflection is the posterior pelvis. Radiation enteritis is avoided by using fields limiting high radiation doses to this volume. Prone positioning to prevent irradiation of loops of small bowel will also decrease complications. The treatment fields should centre on the site of the resected tumour and include the lateral pelvic nodes. The postoperative radiotherapy should commence as soon as possible but must be within six weeks of resection. The dosage ranges suggested are 40- '9 although it is standard practice in the LISA to combine levamisole with 5-fluorouracil in treatment of colorectal cancer. The mechanism of action of levamisole is unclear and 5-fluorouracil alone may be responsible for the observed effects on survival in trials on the combination of 5-fluorouracil and levamisole. 20 The North Central Cancer Treatment Group (NCCTG )21 compared 5-fluorouracil plus levamisole against levamisole and controls. They also showed increased survival with combination chemotherapy in Dukes' C patients. A larger intergroup study was performed to confirm these results and enrolled three time more patients.22 They showed that this combination chemotherapy increased survival in Dukes' C patients by 33% and decreased recurrence by 41%. Levamisole alone was no better than the untreated controls. There was no clear benefit in patients with Dukes' B disease. The addition of folinic acid to 5-fluorouracil resulted in improvements in response, quality of life and survival in the NCCTG study in advanced colorectal cancer.23 There is also considerable discussion on the best route for administering adjuvant chemotherapy -intrahepatic, intraperitoneal, intraportal or intravenous. Of these, the latter two are of most current interest. Hepatic metastases are the commonest cause of failure following surgery for colorectal cancer and these presumably arise from haematogenous spread via the portal vein. Portal infusions are an attempt to target the chemotherapy to the liver and to limit toxicity. These are usually given in conjunction with heparin for a short period of about a week. The treatment is well tolerated without significant hepatic toxicity24 but results have been very conflicting. Taylor et al 25 showed significant improvement in survival following portal vein infusions of 5-fluorouracil particularly in Dukes' B lesions. The NSABP conducted a similar, but much larger trial of seven day portal vein infusion of 5-fluorouracil versus no postoperative adjuvant treatment in Dukes' A, B and C disease.26 They observed an 8% improvement in survival with intraportal 5-fluorouracil but no reduction in clinically detectable hepatic metastases. The Large Bowel Cancer Project failed to reveal any improvement in survival or incidence of liver metastases with intra-portal 5-fluorouracil and heparin infusio.24 There is no evidence currently that portal-vein infusion is superior to systemic intravenous administration. The NSABP recently reported a trial designed to evaluate the efficacy of folinic acid-modulated 5-fluorouracil in adjuvant therapy of Dukes' B and C colon cancer.27 They found that folinic acid and 5-fluorouracil treatment significantly prolongs disease-free survival with a 32% reduction in mortality risk compared to a control group randomised to receive lomustine, vincristine and 5-fluorouracil. Further evidence that modulated 5-fluorouracil may be beneficial came in a meta-analysis of nine randomised prospective clinical trials with 1381 patients with advanced colorectal cancer; this demonstrated a 23% objective response rate with folinic acid and 5-fluorouracil.28
Radiotherapy Trials
The object of adjuvant radiotherapy is to prevent the further growth of cancer cells not removed at the time of surgery. Radiotherapy results in cytotoxicity principally by damaging DNA, thereby interfering with the ability of cells to reproduce. It was initially thought that adjuvant radiotherapy after surgery for rectal cancer would reduce the risk of local recurrence and thereby improve survival rates. The incidence of pelvic recurrence is variable, with figures of 10% to 40% commonly quoted. 29 The risk of recurrence increases with worsening Dukes' stage.30 The first site of recurrence found at re-operation is often the general area of the primary cancer31 and studies have also shown that prevention of recurrence in the area of the primary tumour is associated with a decreased incidence of distant metastase.32 Pelvic recurrence may be associated with both microscopic extension of tumour to the lateral resection margins33 and metastases in unresected pelvic wall lymph nodes. 34 The following studies examined the outcome after curative surgery with or without postoperative radiotherapy in Dukes' B or C colorectal cancer. The
Gastrointestinal Tumor Study Group35 showed a 9% increase in five year survival and 4% reduction in both local and extrapelvic recurrence with adjuvant radiotherapy. The National Surgical Adjuvant Breast and Bowel Project36 showed a 3% decrease in five year survival, 9% improvement in local recurrence and 5% worsening in extrapelvic recurrence with radiation. The Denmark study37 showed that radiotherapy caused no change in five year survival, a 2% decrease in local recurrence and a 2% increase in extrapelvic recurrence. The Netherlands study38 showed a 10% decrease in five year survival, 9% improvement in local recurrence and 12% worsening in extrapelvic recurrence. Overall, these studies have shown that radiotherapy as the sole adjuvant therapy, given either pre-or post-operatively, will reduce pelvic recurrence but not markedly influence either survival rates or extrapelvic recurrence.29 Reduction in pelvic recurrence is worthwhile as this is often difficult or impossible to control, and symptoms are often severe and result in a very poor quality of life.
Combined radiotherapy and chemotherapy trials The failure of adjuvant chemotherapy to lower pelvic recurrence and of adjuvant radiotherapy to lower extrapelvic recurrence or mortality rates has resulted in establishment of trials of adjuvant combination therapy. The following studies examined the outcome after curative surgery and postoperative radiotherapy with or without chemotherapy in Dukes' B and C colorectal cancer. The Gastrointestinal Tumor Study Group35 39 trial had five year survivals of 43% with surgery alone, 52% with adjuvant radiotherapy and 59% with combination radiotherapy and chemotherapy. The local recurrence rates were 24%, 20% and 1 1% respectively and extrapelvic recurrence rates 34%, 30% and 26%. The NCCTG trial40 had five year survival of 47% for adjuvant radiotherapy and 58% for adjuvant combination therapy. The local recurrence rates were 25% and 14% respectively, and extrapelvic recurrence rates 46% and 29%. Another study,41 however, showed no significant improvement in survival with combination chemotherapy and radiotherapy over one or other of the adjuvant modalities alone. The combinations of radiotherapy and chemotherapy used in the trials described were fairly well tolerated. The risks of serious late morbidity such as enteritis and treatment-related mortality were broadly similar to those of patients treated with radiotherapy alone. Conclusion Previous trials of adjuvant therapy in colorectal cancer have suggested a modest survival benefit. Recent evidence shows that modulation of 5-fluorouracil with folinic acid results in greater efficacy with acceptable toxicity. We believe that a local, randomised, controlled trial can accrue sufficient patients to allow us to demonstrate whether adjuvant therapy ofcolorectal cancer using modulated 5-fluorouracil provides worthwhile improvement in survival in this common disease.
